Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Patel A, Hoda RS, Hoda SA. Papillary Breast Tumors: Continuing Controversies and Commentary on WHO's 2019 Criteria and Classification. Int J Surg Pathol. 2021:10668969211035843.

Johncilla M, Elsoukkary S, Jessurun J. The significance of focally enhanced gastritis in haematopoietic stem cell transplant recipients. Histopathology. 2021;79(4):599-606.

Crawford JM, Aguero-Rosenfeld ME, Aifantis I, Cadoff EM, Cangiarella JF, Cordon-Cardo C, et al. The New York State SARS-CoV-2 Testing Consortium: Regional Communication in Response to the COVID-19 Pandemic. Acad Pathol. 2021;8:23742895211006818.

Sussman RT, Manning B, Ackerman D, Bigdeli A, Pammer P, Velu PD, et al. Interpretative differences of combined cytogenetic and molecular profiling highlights differences between MRC and ELN classifications of AML. Cancer Genet. 2021;256-257:68-76.

DeSimone RA, Vinchi F. Screening out the Exposome to Improve Transfusion Quality. Hemasphere. 2021;5(7):e605.

Gao J, Fu L, Lu X, Sukhanova M, Frankfurt O, Mohtashamian A, et al. Mast cell sarcoma transdifferentiated from clonally-related T-lymphoblastic leukemia upon acquisition of mutation and genetic complexity. Leuk Lymphoma. 2021:1-4.

Sun D, Zhao Z, Spiegel S, Liu Y, Fan J, Amrollahi P, et al. Dye-free spectrophotometric measurement of nucleic acid-to-protein ratio for cell-selective extracellular vesicle discrimination. Biosens Bioelectron. 2021;179:113058.

Racine-Brzostek SE, Karbaschi M, Gaebler C, Klasse PJ, Yee J, Caskey M, et al. TOP-Plus is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability. medRxiv. 2021.

Chapel DB, Lee EK, Da Silva AF, Teschan N, Feltmate C, Matulonis UA, et al. Mural nodules in mucinous ovarian tumors represent a morphologic spectrum of clonal neoplasms: a morphologic, immunohistochemical, and molecular analysis of 13 cases. Mod Pathol. 2021;34(3):613-626.

Sun M, Schaap A, Robinson BD, Nanus DM, Tagawa ST. A case report of a patient with plasmacytoid urothelial cancer with significant response to HER2-targeting therapy and enfortumab vedotin. Am J Clin Exp Urol. 2021;9(5):390-396.